Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.